Edition:
India

Sorrento Therapeutics Inc (SRNE.OQ)

SRNE.OQ on NASDAQ Stock Exchange Capital Market

2.41USD
16 Sep 2019
Change (% chg)

-- (--)
Prev Close
$2.41
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
256,851
52-wk High
$6.50
52-wk Low
$1.80

Latest Key Developments (Source: Significant Developments)

Sorrento Therapeutics Files Prospectus Relates To Resale By Selling Stockholders Of Up To 1.3 Mln Co's Common Shares
Tuesday, 18 Jun 2019 

June 17 (Reuters) - Sorrento Therapeutics Inc ::SORRENTO THERAPEUTICS INC FILES PROSPECTUS RELATES TO RESALE BY SELLING STOCKHOLDERS OF UP TO 1.3 MILLION CO'S COMMON SHARES - SEC FILING.  Full Article

Sorrento Therapeutics Says SP-102 Pivotal Phase 3 Trial Remains On Track For Completion In H1 2020
Wednesday, 5 Jun 2019 

June 5 (Reuters) - Sorrento Therapeutics Inc ::SORRENTO THERAPEUTICS INC - SP-102 PIVOTAL PHASE 3 TRIAL REMAINS ON TRACK FOR COMPLETION IN H1 2020.SORRENTO THERAPEUTICS INC - ZTLIDO(®) 5.4% (3 X STRENGTH) TRIAL TO BE INITIATED IN 2019 FOR LOWER BACK PAIN INDICATION.SORRENTO THERAPEUTICS INC - ZTLIDO(®) GROSS SALES GREW FROM APPROXIMATELY $1 MILLION IN MARCH TO $2.4 MILLION IN APRIL AND $3.3 MILLION IN MAY.  Full Article

Sorrento Therapeutics Files Legal Actions Against Patrick Soon-Shiong And Entities Controlled By Him
Wednesday, 3 Apr 2019 

April 3 (Reuters) - Sorrento Therapeutics Inc ::SORRENTO THERAPEUTICS - FILED LEGAL ACTIONS AGAINST PATRICK SOON-SHIONG AND ENTITIES CONTROLLED BY HIM.SORRENTO THERAPEUTICS - LEGAL ACTIONS ASSERT CLAIMS FOR FRAUD, BREACH OF CONTRACT, ARISING OUT OF SOON-SHIONG S PURCHASE OF DRUG CYNVILOQ!" IN MAY 2015.SORRENTO THERAPEUTICS - ARBITRATION DEMAND AGAINST NANTPHARMA, SOON-SHIONG SEEKS DAMAGES IN EXCESS OF $1 BILLION RELATED TO ALLEGED FRAUD AND BREACHES OF AGREEMENT.  Full Article

Sorrento Therapeutics Files For Resale Of 6.3 Mln Shares Of Co By Investors
Thursday, 13 Dec 2018 

Dec 13 (Reuters) - Sorrento Therapeutics Inc ::SORRENTO THERAPEUTICS FILES FOR RESALE OF 6.3 MILLION SHARES OF CO BY INVESTORS - SEC FILING.  Full Article

Sorrento Acquires Sofusa Lymphatic Delivery Technology Platform
Tuesday, 3 Jul 2018 

July 3 (Reuters) - Sorrento Therapeutics Inc ::SORRENTO ACQUIRES THE SOFUSA™ LYMPHATIC DELIVERY PLATFORM FOR IMMUNE-ONCOLOGY (I-O) ANTIBODY THERAPEUTICS.SORRENTO THERAPEUTICS INC - ACQUIRED SOFUSA LYMPHATIC DELIVERY TECHNOLOGY PLATFORM FROM KIMBERLY-CLARK CORPORATION.  Full Article

Sorrento Therapeutics Enteres Into Securities Purchase Agreement
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Sorrento Therapeutics Inc ::SORRENTO THERAPEUTICS SAYS ON DEC 11, CO ENTERED INTO SECURITIES PURCHASE AGREEMENT - SEC FILING.SORRENTO THERAPEUTICS SAYS AGREED TO ISSUE, SELL TO PURCHASERS, IN A PRIVATE PLACEMENT, CONVERTIBLE PROMISSORY NOTES IN OF $50 MILLION.  Full Article

Sorrento Therapeutics says co entered into an at market issuance sales agreement with B. Riley FBR as sales agent
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Sorrento Therapeutics Inc :Sorrento Therapeutics - ‍On Nov. 9, 2017, co entered into an at market issuance sales agreement with B. Riley FBR, Inc., as sales agent - SEC Filing​.Sorrento Therapeutics Inc - ‍ Pursuant to sales agreement, co may offer and sell through agent up to $100 million in shares of common stock​.  Full Article

Sorrento Therapeutics files for mixed shelf of upto $350 mln
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Sorrento Therapeutics Inc :Sorrento Therapeutics Inc files for mixed shelf of upto $350 million - SEC filing‍​.  Full Article